Nebenwirkungen · Myqorzo
MYQORZO 5 mg film-coated tablets MYQORZO 10 mg film-coated tablets MYQORZO 15 mg film-coated tablets MYQORZO 20 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 11
HOS-152259 · Präparat HOS-100709
In SEQUOIA-HCM, adverse events of hypertension were reported more commonly in the aficamten group compared with the placebo group (7.7% versus 2.1%). The mean increases of blood pressure associated with aficamten treatment were 2.3 mmHg for systolic blood pressure, and 3.1 mmHg for diastolic blood pressure. Most reports of hypertension were in patients with a history of hypertension, and all reports were non-serious and mild or moderate in severity. Aficamten-associated increases in blood pressure are thought to be a consequence of relief of LVOT obstruction with improved cardiac output.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-01T08:50:00Z · SHA-256 369c19a3246fa4a58dbc8c7ed499fb343945881c6f2777572242e8ef6b1a416e · Passage 2b18f30d24a47c3182551508bfbe54c738fe078dbecebd27251ce92a79c7b9db · Zeichen 1933–2527 im Abschnitt